Inactive Instrument

Arix Bioscience plc

ARIX

GB00BD045071

Investment Management & Fund Operators

Arix Bioscience net asset value falls at the end of January

February 07, 2023 at 04:32 pm EST

(Alliance News) - Arix Bioscience PLC said on Monday its net asset value at January 31 was 180 pence, down from 182p at the end of October, 2022.

London-based Arix added its total portfolio NAV at January 31 was GBP232.9 million, down from GBP235.4 as of October 31, 2022.

Arix Bioscience is a venture capital company focused on investing in biotechnology companies. Shares in firm closed up 2.80% at 110p in London on Tuesday.

By Jeremy Cutler, Alliance News reporter.

Comments and questions to newsroom@alliancenews.com.

Latest news about Arix Bioscience plc

Merck Sharp & Dohme LLC completed the acquisition of Harpoon Therapeutics, Inc..	Mar. 10	CI
RTW Biotech Opportunities NAV increases 2.5% in January	Feb. 14	AN
RTW Biotech Opportunities Completes Arix Bioscience Acquisition	Feb. 13	MT
RTW Biotech Opportunities Ltd a fund managed by RTW Investments, LP completed the acquisition of Arix Biosciences Plc's assets from Arix Bioscience plc.	Feb. 12	CI
Katoro Gold launches fundraising, eyes board shake-up	Feb. 12	AN
Arix Bioscience's Asset Sale to RTW Biotech Takes Effect	Feb. 12	MT
Arix Bioscience shares suspended ahead of RTW takeover	Feb. 12	AN
Arix Bioscience Shares to be Suspended on London Exchange Amid Acquisition	Feb. 12	MT
Arix Bioscience Shareholders Approve Asset Sale to RTW Biotech	Jan. 29	MT
Arix Bioscience Gains UK Regulatory Approval for Sale to RTW Biotech	Jan. 23	MT
RTW Biotech completes Arix investment in takeover run-up	Jan. 22	AN
RTW Biotech Buys Minority Stake in Arix Bioscience to Support Planned Takeover	Jan. 22	MT
Arix Bioscience plc Announces Resignation of Directors	Jan. 22	CI
Arix Bioscience eyes USD19 million return from Harpoon sale	Jan. 19	AN
Arix Bioscience Flags Proceeds from Merck's Purchase of Harpoon Therapeutics	Jan. 19	MT
Rtw Biotech Opportunities Operating Ltd completed the acquisition of a 26.6% stake in Arix Bioscience plc from Acacia Research Corporation for £47.2 million.	Jan. 18	CI
Arix Bioscience's Portfolio Company Signs $680 Million Takeover Deal with Merck & Co.	Jan. 08	MT
Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. for $410 million.	Jan. 07	CI
Arix Bioscience's Portfolio Company Doses First Patient in Late-stage Trial of Choroidal Melanoma Therapy	Dec. 08	MT
RTW Biotech Opportunities Ltd a fund managed by RTW Investments, LP agreed to acquire Arix Biosciences Plc's assets from Arix Bioscience plc for £190 million.	Nov. 30	CI
FTSE 100 Closes Up 0.28% as Interest Rate Rise Fears Start to Ease	Nov. 01	DJ
RTW Biotech agrees "immediately accretive" Arix Bioscience takeover	Nov. 01	AN
RTW Biotech Opportunities, Arix Bioscience Agree on Potential Merger Terms	Nov. 01	MT
Rtw Biotech Opportunities Operating Ltd enter into an agreement to acquire 26.6% stake in Arix Bioscience plc from Acacia Research Corporation for £47.2 million.	Oct. 31	CI
Transcript : RTW Biotech Opportunities Ltd, Arix Bioscience plc - Pre Recorded M&A Call	Oct. 31

Arix Bioscience plc is a United Kingdom-based global venture capital company. The Company is focused on investing in biotechnology companies to deliver superior risk-adjusted returns to shareholders. The Company is engaged in sourcing, financing, and developing healthcare and life science businesses globally. It focuses on late pre-clinical to clinical-stage ventures and covers a diversified range of therapeutic areas. The Company's core portfolio includes Artios Pharma Limited, Aura Biosciences, Inc., Disc Medicine Inc., Ensoma, Harpoon Therapeutics, Inc., Imara, Inc., and Iterum Therapeutics Limited. Its program includes AU-011, ART4215 + talazoparib, Bitopertin, HPN328, HPN217, ART0380, ART4215, and DISC-0974. It has approximately 11 clinical trials and is conducting nine pre-clinical studies. The Company's subsidiaries include Arix Bioscience Holdings Limited, Arix Bioscience, Inc, Arix Capital Management Limited, Arthurian Life Sciences GP Limited, and ALS SPV Limited.

Sector

Investment Management & Fund Operators

Calendar

2024-04-22 - Q4 2023 Earnings Release (Projected)

More about the company

Sector Venture Capital

	1st Jan change	Capi.
UMBRA COMPANIES INC.	+31.41%	12.02B
HERCULES CAPITAL, INC.	+9.72%	2.91B
HBM HEALTHCARE INVESTMENTS AG	+1.42%	1.41B
OCTOPUS TITAN VCT PLC	-8.46%	1.22B
CION INVESTMENT CORPORATION	-1.95%	594M
VERUSA HOLDING	+46.95%	567M
MOLTEN VENTURES PLC	-20.39%	511M
WOORI TECHNOLOGY INVESTMENT CO., LTD	+36.49%	495M
OCTOPUS APOLLO VCT PLC	-4.17%	492M

Venture Capital

Arix Bioscience plc

Equities

ARIX

GB00BD045071

Investment Management & Fund Operators

Arix Bioscience net asset value falls at the end of January

Latest news about Arix Bioscience plc

Chart Arix Bioscience plc

Company Profile

Sector Venture Capital